Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort

English version České info

Background:
Pregnancy in women with systemic lupus erythematosus (SLE) or antiphospholipid antibodies (APL Ab)—autoimmune conditions characterized by complement-mediated injury—is associated with increased risk of preeclampsia and miscarriage. Our previous studies in mice indicate that complement activation targeted to the placenta drives angiogenic imbalance and placental insufficiency.

Methods and Findings:
We use PROMISSE, a prospective study of 250 pregnant patients with SLE and/or APL Ab, to test the hypothesis in humans that impaired capacity to limit complement activation predisposes to preeclampsia. We sequenced genes encoding three complement regulatory proteins—membrane cofactor protein (MCP), complement factor I (CFI), and complement factor H (CFH)—in 40 patients who had preeclampsia and found heterozygous mutations in seven (18%). Five of these patients had risk variants in MCP or CFI that were previously identified in atypical hemolytic uremic syndrome, a disease characterized by endothelial damage. One had a novel mutation in MCP that impairs regulation of C4b. These findings constitute, to our knowledge, the first genetic defects associated with preeclampsia in SLE and/or APL Ab. We confirmed the association of hypomorphic variants of MCP and CFI in a cohort of non-autoimmune preeclampsia patients in which five of 59 were heterozygous for mutations.

Conclusion:
The presence of risk variants in complement regulatory proteins in patients with SLE and/or APL Ab who develop preeclampsia, as well as in preeclampsia patients lacking autoimmune disease, links complement activation to disease pathogenesis and suggests new targets for treatment of this important public health problem.

Study Registration:
ClinicalTrials.gov NCT00198068

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1001013
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001013

Souhrn

Study Registration:
ClinicalTrials.gov NCT00198068

: Please see later in the article for the Editors' Summary

Zdroje

1. IlekisJVReddyUMRobertsJM 2007 Preeclampsia—a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 14 508 523

2. MaynardSEpsteinFHKarumanchiSA 2008 Preeclampsia and angiogenic imbalance. Annu Rev Med 59 61 78

3. YoungBCLevineRJKarumanchiSA 2010 Pathogenesis of preeclampsia. Annu Rev Pathol 5 173 192

4. EsplinMSFausettMBFraserAKerberRMineauG 2001 Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 344 867 872

5. GirardiGYarilinDThurmanJMHolersVMSalmonJE 2006 Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 203 2165 2175

6. QingXRedechaPBBurmeisterMATomlinsonSD'AgatiVD 2010 Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 2010 Oct 13 [Epub ahead of print]

7. MaoDWuXDeppongCFriendLDDoleckiG 2003 Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity 19 813 822

8. LynchAMGibbsRSMurphyJRByersTNevilleMC 2008 Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 199 354 e351 358

9. TincaniABazzaniCZingarelliSLojaconoA 2008 Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 34 267 273

10. ShamonkiJMSalmonJEHyjekEBaergenRN 2007 Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 196 167 e161 165

11. GirardiGBullaRSalmonJETedescoF 2006 The complement system in the pathophysiology of pregnancy. Mol Immunol 43 68 77

12. CaprioliJNorisMBrioschiSPianettiGCastellettiF 2006 Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108 1267 1279

13. NorisMRemuzziG 2009 Atypical hemolytic-uremic syndrome. N Engl J Med 361 1676 1687

14. FangCJFremeaux-BacchiVLiszewskiMKPianettiGNorisM 2008 Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 111 624 632

15. KavanaghDRichardsAAtkinsonJ 2008 Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 59 293 309

16. 2002 ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99 159 167

17. 2007 Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 661 678

18. BurtonPRClaytonDGCardonLRCraddockNDeloukasP 2007 Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39 1329 1337

19. Fremeaux-BacchiVDragon-DureyMABlouinJVigneauCKuypersD 2004 Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41 e84

20. Fremeaux-BacchiVMoultonEAKavanaghDDragon-DureyMABlouinJ 2006 Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 17 2017 2025

21. ManolioTACollinsFSCoxNJGoldsteinDBHindorffLA 2009 Finding the missing heritability of complex diseases. Nature 461 747 753

22. LiszewskiMKLeungMCuiWSubramanianVBParkinsonJ 2000 Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 275 37692 37701

23. LiBLealSM 2008 Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 83 311 321

24. LiszewskiMKLeungMKSchramlBGoodshipTHAtkinsonJP 2007 Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 44 1559 1568

25. CasasnovasJMLarvieMStehleT 1999 Crystal structure of two CD46 domains reveals an extended measles virus-binding surface. Embo J 18 2911 2922

26. CohenDKoopmansMKremer HovingaICBergerSPRoos van GroningenM 2008 Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 58 2460 2469

27. RogozinIBMilanesiL 1997 Analysis of donor splice sites in different eukaryotic organisms. J Mol Evol 45 50 59

28. KavanaghDRichardsANorisMHauhartRLiszewskiMK 2008 Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 45 95 105

29. BienaimeFDragon-DureyMARegnierCHNilssonSCKwanWH 2010 Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77 339 349

30. Sellier-LeclercALFremeaux-BacchiVDragon-DureyMAMacherMANiaudetP 2007 Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18 2392 2400

31. FakhouriFRoumeninaLProvotFSalleeMCaillardS 2010 Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21 859 867

32. FakhouriFJablonskiMLepercqJBlouinJBenachiA 2008 Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112 4542 4545

33. FangCJRichardsALiszewskiMKKavanaghDAtkinsonJP 2008 Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol 143 336 348